The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients.

Russell-Jones DL, Watts GF, Weissberger A, Naoumova R, Myers J, Thompson GR, Sönksen PH

Clinical endocrinology1 Sept 1994Cited by 78 (Europe PMC)

PMID7955441DOI10.1111/j.1365-2265.1994.tb02555.xPepBankPUB-07955441

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

01HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, rhGH reduced serum cholesterol from 6.44 +/- 0.49 to 5.71 +/- 0.48 mmol/l (P < 0.01).
In plain wordsIn GH-deficient adults, serum cholesterol decreased during rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseSerum cholesterol
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month · 2 monthsAs given in this study (human).
Measurements
Serum cholesterol
6.44 mmol/l
baseline
Serum cholesterol
5.71 mmol/l
after treatment
Reported uncertainty
0.49 mmol/l
baseline
Reported uncertainty
0.48 mmol/l
after treatment
Source sentences
Summary
In the rhGH treated group there was a significant fall in serum cholesterol (P < 0.01) (6.44 +/- 0.49 to 5.71 +/- 0.48 mmol/l)
3 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomly allocated to placebo or rhGH replacement therapy (0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month).
Summary · context
Eighteen patients with severe growth hormone deficiency.
Summary · context
Fasting lipid, lipoprotein and cholesterol precursors (lathosterol and mevalonic acid) were measured at baseline and after 2 months.
Report a problemFND-0795544101
02HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, rhGH reduced LDL cholesterol from 4.29 +/- 0.49 to 3.62 +/- 0.44 mmol/l (P < 0.02).
In plain wordsIn GH-deficient adults, LDL cholesterol decreased during rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseLDL cholesterol
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month · 2 monthsAs given in this study (human).
Measurements
LDL cholesterol
4.29 mmol/l
baseline
LDL cholesterol
3.62 mmol/l
after treatment
Reported uncertainty
0.49 mmol/l
baseline
Reported uncertainty
0.44 mmol/l
after treatment
Source sentences
Summary
LDL cholesterol (P < 0.02) (4.29 +/- 0.49 to 3.62 +/- 0.44 mmol/l)
3 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomly allocated to placebo or rhGH replacement therapy (0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month).
Summary · context
Eighteen patients with severe growth hormone deficiency.
Summary · context
Fasting lipid, lipoprotein and cholesterol precursors (lathosterol and mevalonic acid) were measured at baseline and after 2 months.
Report a problemFND-0795544102
03HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, rhGH reduced the LDL/HDL ratio from 3.99 +/- 0.62 to 3.26 +/- 0.39 (P < 0.02).
In plain wordsIn GH-deficient adults, the LDL-to-HDL cholesterol ratio decreased during rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseLDL/HDL cholesterol ratio
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month · 2 monthsAs given in this study (human).
Measurements
LDL/HDL ratio
3.99 ratio
baseline
LDL/HDL ratio
3.26 ratio
after treatment
Reported uncertainty
0.62 ratio
baseline
Reported uncertainty
0.39 ratio
after treatment
Source sentences
Summary
LDL cholesterol/HDL cholesterol ratio (P < 0.02) (3.99 +/- 0.62 to 3.26 +/- 0.39)
3 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomly allocated to placebo or rhGH replacement therapy (0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month).
Summary · context
Eighteen patients with severe growth hormone deficiency.
Summary · context
Fasting lipid, lipoprotein and cholesterol precursors (lathosterol and mevalonic acid) were measured at baseline and after 2 months.
Report a problemFND-0795544103
04HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, rhGH reduced apolipoprotein B from 1.30 +/- 0.11 to 1.15 +/- 0.11 g/l (P < 0.01).
In plain wordsIn GH-deficient adults, apolipoprotein B decreased during rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseApolipoprotein B
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month · 2 monthsAs given in this study (human).
Measurements
Apolipoprotein B
1.3 g/l
baseline
Apolipoprotein B
1.15 g/l
after treatment
Reported uncertainty
0.11 g/l
baseline and after treatment
Source sentences
Summary
apolipoprotein B (P < 0.01 (1.30 +/- 0.11 to 1.15 +/- 0.11 g/l)
3 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomly allocated to placebo or rhGH replacement therapy (0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month).
Summary · context
Eighteen patients with severe growth hormone deficiency.
Summary · context
Fasting lipid, lipoprotein and cholesterol precursors (lathosterol and mevalonic acid) were measured at baseline and after 2 months.
Report a problemFND-0795544104
05HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, rhGH reduced mevalonic acid from 13.4 +/- 10.96 to 6.21 +/- 1.91 micrograms/l (P < 0.05).
In plain wordsIn GH-deficient adults, mevalonic acid decreased during rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseMevalonic acid
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month · 2 monthsAs given in this study (human).
Measurements
Mevalonic acid
13.4 micrograms/l
baseline
Mevalonic acid
6.21 micrograms/l
after treatment
Reported uncertainty
10.96 micrograms/l
baseline
Reported uncertainty
1.91 micrograms/l
after treatment
Source sentences
Summary
mevalonic acid (P < 0.05) (13.4 +/- 10.96 to 6.21 +/- 1.91 micrograms/l).
3 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomly allocated to placebo or rhGH replacement therapy (0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month).
Summary · context
Eighteen patients with severe growth hormone deficiency.
Summary · context
Fasting lipid, lipoprotein and cholesterol precursors (lathosterol and mevalonic acid) were measured at baseline and after 2 months.
Report a problemFND-0795544105
06HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, triglyceride concentrations did not change significantly during rhGH treatment.
In plain wordsIn GH-deficient adults, triglycerides did not change significantly during rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeTriglycerides
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month · 2 monthsAs given in this study (human).
Source sentences
Summary
There were no significant changes in triglycerides, HDL cholesterol, apolipoprotein A1, lipoprotein (a) or lathosterol concentrations.
3 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomly allocated to placebo or rhGH replacement therapy (0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month).
Summary · context
Eighteen patients with severe growth hormone deficiency.
Summary · context
Fasting lipid, lipoprotein and cholesterol precursors (lathosterol and mevalonic acid) were measured at baseline and after 2 months.
Report a problemFND-0795544106
07HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, HDL cholesterol did not change significantly during rhGH treatment.
In plain wordsIn GH-deficient adults, HDL cholesterol did not change significantly during rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeHDL cholesterol
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month · 2 monthsAs given in this study (human).
Source sentences
Summary
There were no significant changes in triglycerides, HDL cholesterol, apolipoprotein A1, lipoprotein (a) or lathosterol concentrations.
3 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomly allocated to placebo or rhGH replacement therapy (0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month).
Summary · context
Eighteen patients with severe growth hormone deficiency.
Summary · context
Fasting lipid, lipoprotein and cholesterol precursors (lathosterol and mevalonic acid) were measured at baseline and after 2 months.
Report a problemFND-0795544107
08HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, apolipoprotein A1 did not change significantly during rhGH treatment.
In plain wordsIn GH-deficient adults, apolipoprotein A1 did not change significantly during rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeApolipoprotein A1
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month · 2 monthsAs given in this study (human).
Source sentences
Summary
There were no significant changes in triglycerides, HDL cholesterol, apolipoprotein A1, lipoprotein (a) or lathosterol concentrations.
3 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomly allocated to placebo or rhGH replacement therapy (0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month).
Summary · context
Eighteen patients with severe growth hormone deficiency.
Summary · context
Fasting lipid, lipoprotein and cholesterol precursors (lathosterol and mevalonic acid) were measured at baseline and after 2 months.
Report a problemFND-0795544108
09HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, lipoprotein (a) did not change significantly during rhGH treatment.
In plain wordsIn GH-deficient adults, lipoprotein (a) did not change significantly during rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeLipoprotein (a)
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month · 2 monthsAs given in this study (human).
Source sentences
Summary
There were no significant changes in triglycerides, HDL cholesterol, apolipoprotein A1, lipoprotein (a) or lathosterol concentrations.
3 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomly allocated to placebo or rhGH replacement therapy (0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month).
Summary · context
Eighteen patients with severe growth hormone deficiency.
Summary · context
Fasting lipid, lipoprotein and cholesterol precursors (lathosterol and mevalonic acid) were measured at baseline and after 2 months.
Report a problemFND-0795544109
10HumanNon-randomized trialEfficacy outcome
In GH-deficient adults, lathosterol did not change significantly during rhGH treatment.
In plain wordsIn GH-deficient adults, lathosterol did not change significantly during rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeLathosterol
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month · 2 monthsAs given in this study (human).
Source sentences
Summary
There were no significant changes in triglycerides, HDL cholesterol, apolipoprotein A1, lipoprotein (a) or lathosterol concentrations.
3 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomly allocated to placebo or rhGH replacement therapy (0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month).
Summary · context
Eighteen patients with severe growth hormone deficiency.
Summary · context
Fasting lipid, lipoprotein and cholesterol precursors (lathosterol and mevalonic acid) were measured at baseline and after 2 months.
Report a problemFND-0795544110
11HumanObservational studyMechanism
In GH-deficient adults receiving rhGH, the insulin rise correlated inversely with the cholesterol fall (P < 0.05).
In plain wordsIn GH-deficient adults receiving rhGH, rising insulin was inversely linked to falling cholesterol.
Peptide
HGH (somatotropin)
Outcome
Not applicableInsulin rise and cholesterol fall
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month · 2 monthsAs given in this study (human).
Source sentences
Summary
In the GH treated group the rise in serum insulin was inversely correlated with the fall in cholesterol (P < 0.05), LDL cholesterol (P < 0.01) and apolipoprotein B (P < 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomly allocated to placebo or rhGH replacement therapy (0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month).
Summary · context
Eighteen patients with severe growth hormone deficiency.
Summary · context
Fasting lipid, lipoprotein and cholesterol precursors (lathosterol and mevalonic acid) were measured at baseline and after 2 months.
Report a problemFND-0795544111
12HumanObservational studyMechanism
In GH-deficient adults receiving rhGH, the insulin rise correlated inversely with the LDL cholesterol fall (P < 0.01).
In plain wordsIn GH-deficient adults receiving rhGH, rising insulin was inversely linked to falling LDL cholesterol.
Peptide
HGH (somatotropin)
Outcome
Not applicableInsulin rise and LDL cholesterol fall
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month · 2 monthsAs given in this study (human).
Source sentences
Summary
In the GH treated group the rise in serum insulin was inversely correlated with the fall in cholesterol (P < 0.05), LDL cholesterol (P < 0.01) and apolipoprotein B (P < 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomly allocated to placebo or rhGH replacement therapy (0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month).
Summary · context
Eighteen patients with severe growth hormone deficiency.
Summary · context
Fasting lipid, lipoprotein and cholesterol precursors (lathosterol and mevalonic acid) were measured at baseline and after 2 months.
Report a problemFND-0795544112
13HumanObservational studyMechanism
In GH-deficient adults receiving rhGH, the insulin rise correlated inversely with the apolipoprotein B fall (P < 0.01).
In plain wordsIn GH-deficient adults receiving rhGH, rising insulin was inversely linked to falling apolipoprotein B.
Peptide
HGH (somatotropin)
Outcome
Not applicableInsulin rise and apolipoprotein B fall
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month · 2 monthsAs given in this study (human).
Source sentences
Summary
In the GH treated group the rise in serum insulin was inversely correlated with the fall in cholesterol (P < 0.05), LDL cholesterol (P < 0.01) and apolipoprotein B (P < 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
Patients were randomly allocated to placebo or rhGH replacement therapy (0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month).
Summary · context
Eighteen patients with severe growth hormone deficiency.
Summary · context
Fasting lipid, lipoprotein and cholesterol precursors (lathosterol and mevalonic acid) were measured at baseline and after 2 months.
Report a problemFND-0795544113

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.